Stocksigma LogoStocksigma Logo

Biocon Secures US FDA Approval for Perjeta Biosimilar Pebrilzo

The US FDA approved Biocon's Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta for treating HER2-positive breast cancer, marking the company鈥檚 fifth

Biocon Secures US FDA Approval for Perjeta Biosimilar Pebrilzo

Biocon Ltd 路 Press Release 路 16 Nov 2026, 2:06 pm

Biocon Secures US FDA Approval for Perjeta Biosimilar Pebrilzo The US FDA approved Biocon's Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta for treating HER2-positive breast cancer, marking the company鈥檚 fifth approved oncology biosimilar in the US. Biocon also finalized a global settlement and licensing agreement with Genentech, establishing the earliest licensed US commercial launch date in Q3'CY28. This follows a positive CHMP opinion received in Sep'26 recommending European marketing authorization. Pebrilzo expands Biocon鈥檚 commercial oncology portfolio alongside Ogivri, Jobevne, Fulphila, and Aukelso, with multiple additional biosimilar assets progressing in its pipeline.

Original exchange filing (PDF)

More announcements from Biocon Ltd

All Biocon Ltd announcements